Common side effects include nausea, vomiting, and changes in appetite during dose escalation, which typically resolve within days to weeks
Another study published by Diabetes, Obesity & Metabolism in June 2025 further supported this link, concluding that the five-year risk of developing NAION doubled in patients using GLP-1 drugs compared to non-users
With the global scale of obesity, further scientific innovation and therapy options are needed to meet every individual's needs and preferences, said Martin Holst Lange, chief scientific officer and executive vice president of Research & Development at Novo Nordisk
Compounding factors and combination strategies Sometimes the answer is not just one thing
The Nrf2/ARE pathway, which controls redox homeostasis and fights against ferroptosis, is another regulatory component